A.D. Beadell Investment Counsel’s Novo Nordisk NVO Stock Holding History

A.D. Beadell Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Sell	33,438 -400	-1%	-$17.2K	1.03%	34
2026 Q1	$1.24M	Sell	33,838 -1,995	-6%	-$94.5K	0.79%	44
2025 Q4	$1.82K	Buy	35,833 +1,605	+5%	+$82.1K	1.18%	31
2025 Q3	$1.9M	Buy	34,228 +9,450	+38%	+$553K	1.29%	29
2025 Q2	$1.71M	Buy	24,778 +7,193	+41%	+$489K	1.3%	29
2025 Q1	$1.22M	Buy	17,585 +4,573	+35%	+$378K	1.02%	37
2024 Q4	$1.12M	Buy	13,012 +3,787	+41%	+$410K	0.91%	39
2024 Q3	$1.1M	Hold	9,225	–	–	0.88%	40
2024 Q2	$1.32M	Buy	9,225 +3,745	+68%	+$496K	1.1%	35
2024 Q1	$703K	Buy	5,480 +255	+5%	+$30.4K	0.61%	51
2023 Q4	$540K	Buy	+5,225	New	+$517K	0.51%	53

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

A.D. Beadell Investment Counsel's NVO Position: Q2 2026 in Review

A.D. Beadell Investment Counsel reduced its Novo Nordisk (NVO) stake by 1.2% in Q2 2026, selling an estimated $17.2K and leaving 33,438 shares worth $1.6M. The position accounts for 1.03% of the portfolio, ranked #34.

A.D. Beadell Investment Counsel first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.9M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

A.D. Beadell Investment Counsel held 33,438 shares of Novo Nordisk worth $1.6M as of Q2 2026.
A.D. Beadell Investment Counsel sold 400 Novo Nordisk shares in Q2 2026, an estimated $17.2K.
Novo Nordisk made up 1.03% of A.D. Beadell Investment Counsel's portfolio in Q2 2026, its #34 holding.
A.D. Beadell Investment Counsel first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
A.D. Beadell Investment Counsel's Novo Nordisk position peaked at $1.9M in Q3 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on A.D. Beadell Investment Counsel's 13F filing for Q2 2026, filed 15 Jul 2026.